Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease
Clicks: 1
ID: 319037
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #82 of 85 articles by views in inflammatory bowel diseases
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Death receptor 3 (DR3; also termed tumor necrosis factor receptor superfamily member 25 [TNFRSF25]) is the sole functional receptor for tumor necrosis factor (TNF)-like cytokine 1A (TL1A) and is constitutively expressed on effector lymphoid cells in peripheral blood and in both inflamed and adjacent noninflamed tissues. Excessive DR3 signaling contributes to chronic inflammation in inflammatory bowel disease (IBD). While clinical trials of anti-TL1A antibodies have demonstrated efficacy in ulcerative colitis and Crohn disease, the stable expression pattern of DR3 suggests that receptor blockade may more effectively and durably inhibit TL1A-driven proinflammatory signaling and limit disease propagation. We describe the preclinical development of SL-325, a fully human, Fc-silent, high-affinity DR3-blocking monoclonal antibody. METHODS: Binding affinity and specificity of SL-325 were evaluated using biophysical and cell-based assays. Functional activity was assessed in peripheral blood mononuclear cells (PBMCs) from healthy donors and IBD patients, an ex vivo human intestinal inflammation model, and cynomolgus macaque toxicology studies. RESULTS: SL-325 bound to human DR3 with picomolar affinity and high specificity while potently blocking TL1A binding without inducing DR3 agonism. SL-325 suppressed TL1A-induced proinflammatory cytokine secretion in PBMCs from healthy donors and IBD patients. In an ex vivo human intestinal model, SL-325 inhibited TL1A-driven cytokine production and preserved epithelial barrier integrity. In nonhuman primates, SL-325 was safe and well tolerated at doses up to 100 mg/kg, demonstrated dose-proportional pharmacokinetics, and led to prolonged DR3 receptor occupancy (RO) without immune activation or proliferation. CONCLUSION: These data demonstrate that SL-325 is a novel DR3-blocking antibody with the potential to provide durable inhibition of the TL1A/DR3 axis and support the clinical development of SL-325 to treat IBD.
| Reference Key |
openalex_W7166317127
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mahmud Hussain, Anne Y. Lai, Derek Franklin, Karen Lenz, Arpita Patel, Noah Murr, Harunobu Kato, Lini Pandite, Taylor H. Schreiber, Suresh de Silva |
| Journal | inflammatory bowel diseases |
| Year | 2026 |
| DOI |
10.1093/ibd/izag101
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.